Has anyone tried calocurb (amarsate) for appetite reduction/GLP-1 agonism?

#1

I saw it at A4M… Not sure if convinced (esp b/c I have semaglutide now), but semaglutide injectables allow less precision of delivery…

#2

Alex what is your thought about semaglutide and the broader class of drugs increasing insulin and that effect on aging?

#3

Idk, semaglutide has SO many effects and is robustly shown to be anti-aging across numerous axis now so it’s worth it

in any case, it seems to really only work for a few days, after which my appetite almost fully rebounds…

==
calocurb has a “30 day money back guarantee”, I wonder if they ask questions. Says this: “If you are one of the small number of people our natural GLP-1 activator is not ideal for, we will refund your first order.”

It’s really useful for travel especially when you want to ideally reduce your temptation to seagull

#4

Do researchers know this for sure and the mechanisms?

#5

Have it now. Will try higher doses, but not too much to induce nausea. I don’t expect it to work but I’m trying anyways

==
Aug29: asked for a refund. It’s not reducing my overall calorie consumption each day by much, if anything

#6

There’s now evolv.
Evolv | Evolv

I’ll try one. They have money back guarantee and I am still injection averse so I need all routes. I’m only trying bc of the money back guarantee

https://x.com/cremieuxrecueil/status/1958255278744556010?s=19

#7

You would wonder what those billions invested in orforglipron, and amycretin are for…

“Supports GLP1” is my new favorite scam. Seems more subtle than oral/sublingual tirzepatide.

#8

Short answer: there’s no independent evidence right now that Evolv’s “EV1-peptide” actually stimulates GLP-1 in humans.

What’s out there:

  • Evolv’s own pages say EV1 is a yeast-derived peptide “engineered to mimic” incretins (GLP-1/GIP), with in-vitro receptor activation, some animal work, and an “ongoing 90-day, 120-person” human study—but no published data or trial registration is provided. (evolvlife.com)
  • They market the active as a peptide made in/with baker’s yeast; your “S288C” note refers to the standard lab strain of Saccharomyces cerevisiae (a common chassis), but I can’t find any peer-reviewed paper or patent that documents an “EV1-peptide” from S288C or shows human GLP-1 effects. (yeastgenome.org)

Why the claim is a stretch without data:

  • Native GLP-1 is clipped by DPP-4 and NEP with a ~1–2 minute half-life; that’s why approved GLP-1RAs are heavily modified or use special oral delivery (e.g., semaglutide + SNAC). An orally swallowed, unmodified peptide embedded in yeast biomass would need strong proof of bioavailability and receptor activation to be credible. (PubMed, PMC, NCBI)
  • The “engineered microbe delivers GLP-1 agonism” concept exists in mice, but human data are lacking—and mouse success often doesn’t translate. (BioRxiv)

Bottom line: treat Evolv’s GLP-1 “biomimetic” as unproven until a peer-reviewed human trial (or at least a registered study with released results) shows it raises GLP-1 activity (or GLP-1 levels), alters glucose/OGTT, appetite, and weight versus placebo, with safety data. Right now, all we have are the company’s own assertions. (evolvlife.com)

If you want, I can keep an eye out for a published trial and summarize it when (if) it appears.